GlobeNewsWire
28 Sept 2026, 13:51 UTC · 1h ago
Verdict
Headline takes no side. We score NTHI +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish · 1 new · 3 priced in
NeOnc Technologies is scheduled to meet with the FDA on November 17, 2026, to discuss the Phase 2 trial design and potential accelerated-approval pathway for NEO212.
Newpress release dated Sept 28
More positive than 93% of claims this week
NEO100 Phase 2a data showed six-month progression-free survival of 48.9% against a 20% benchmark and median overall survival of 26.09 months.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
So whatWith an October Type B meeting expected, a successful registrational pathway agreement would support the $20 price target.
More positive than 87% of claims this week
Roth Capital analyst Jonathan Aschoff anticipates potential pivotal-trial starts for NeOnc programs by the end of 2026.
Priced inrefers to 'recently initiated coverage'
So whatMoving to pivotal trials typically triggers significant increases in R&D spend and potential subsequent equity dilution.
More positive than 66% of claims this week
NeOnc completed a registered direct offering in September priced at $4.20 per share including warrants.
Priced inrefers to 'September registered direct offering'
So whatThe $4.20 floor provides a recent valuation benchmark for the stock as it heads into Q4 catalysts.
More positive than 54% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
Positive catalysts including upcoming FDA meetings, promising preliminary clinical data for NEO212 and NEO100, and insider buying.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
4h ago
−1.8%
Price is moving against the score
$3.25 vs $3.31 close before publication (Sep 25) · not market-adjusted
NTHI chart →
